Short report: Fluorescent Leishmania: Application to anti-leishmanial drug testing

American Journal of Tropical Medicine and Hygiene

Volumn 71, Issue 4, 2004, Pages 400-402

  Singh, Neeloo ^a   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MILTEFOSINE; PENTAMIDINE; STIBOGLUCONATE SODIUM;

ARTICLE; CELL SELECTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; FLOW CYTOMETRY; IN VITRO STUDY; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIASIS; NONHUMAN; PARASITE CONTROL; PROMASTIGOTE; PROTEIN EXPRESSION; TARGET CELL;

LEISHMANIA DONOVANI; NASO HEXACANTHUS; PROTOZOA;

EID: 7644225314     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.71.400     Document Type: Article

References (15)

1. Berman JD, 1991. Clinical diagnostic and chemical developments in the last 10 years. Clin Infect Dis 24: 684-703.
2. Desjeux P, 2001. The increase in risk factors for leishmaniasis world-wide. Trans R Soc Trop Med Hyg 95: 239-243.
3. Buckner FS, Verlinde CL, La Flamme AC, van Voorhis WC, 1996. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 40: 2592-2597.
4. Collins LA, Torrero MN, Franzblau SG, 1998. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 344-347.
5. McFadden DC, Seeber F, Boothroyd JC, 1997. Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob Agents Chemother 41: 1849-1853.
6. Roy G, Dumas C, Sereno D, Wu Y, Singh AK, Tremblay MJ, Ouellette M, Olivier M, Papadopoulou B, 2000. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 110: 195-206.
7. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC, 1994. Green fluorescent protein as a marker for gene expression. Science 263: 802-805.
8. Singh N, 2002. Is there true Sb (V) resistance in Indian kala azar field isolates? Curr Sci 83: 101-102.
9. Ha DS, Schwarz JK, Turco SJ, Beverley SM, 1996. Use of the green fluorescent protein as a marker in transfected Leishmania. Mol Biochem Parasitol 77: 57-64.
10. Singh N, Singh RT, Sundar S, 2002. Identification of a gene linked to drug resistance in field isolates of Leishmania donovani. Ann Trop Med Parasitol 96: 839-841.
11. Ganguly NK, 2002. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. TDR News 68: 2.
12. Thakur CP, 1993. Diminishing effectiveness of currently used drugs in treatment of kala azar and amphotericin B in antimony and pentamidine resistant kala azar. Bhaduri, AN, Basu MK, Sen AK, Kumar S, eds. Current Trends in Leishmania Research. New Delhi: Publications and Information Directorate. Council of Scientific and Industrial Research, 254-262.
13. Narain L, Dutta GP, 1978. Cultivation and in vitro chemotherapeutic studies on Leishmania donovani. Indian J Parasitol 2: 83-86.
14. de Jimenez G, Ercoli N, 1965. Effect of drugs on various leishmania isolates and succinic dehydrogenase inhibition. Exp Parasitol 17: 302-308.
15. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D, 1999. Evidence that the high incidence of treatment failures in Indian kala azar is due to the emergence of antimony resistant strains of Leishmania donovani. J Infect Dis 180: 564-567.